Statements (48)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:ledipasvir
gptkb:velpatasvir |
gptkbp:activities |
blocks sodium channels
blocks calcium channels blocks potassium channels |
gptkbp:approves |
gptkb:1985
|
gptkbp:brand |
gptkb:Cordarone
gptkb:Pacerone |
gptkbp:contraindication |
hypersensitivity to amiodarone
second or third degree AV block severe sinus node dysfunction |
gptkbp:financial_products |
D B00529
|
https://www.w3.org/2000/01/rdf-schema#label |
amiodarone
|
gptkbp:ingredients |
C25 H29 I2 N
|
gptkbp:interacts_with |
gptkb:beer
gptkb:digoxin gptkb:warfarin statins |
gptkbp:is_atype_of |
C01 B D01
|
gptkbp:is_available_in |
gptkb:Australia
gptkb:United_Kingdom gptkb:United_States gptkb:Native_American_tribe |
gptkbp:is_available_on |
gptkb:tablet
injection |
gptkbp:is_part_of |
antiarrhythmic therapy
|
gptkbp:is_used_by |
cardiologists
emergency medicine physicians hospital pharmacists |
gptkbp:is_used_for |
treatment of atrial fibrillation
treatment of atrial flutter treatment of ventricular tachycardia |
gptkbp:lifespan |
15 to 100 days
|
gptkbp:manager |
oral
intravenous |
gptkbp:metabolism |
hepatic
|
gptkbp:side_effect |
liver toxicity
thyroid dysfunction skin discoloration pulmonary toxicity |
gptkbp:suitable_for |
pregnant women
nursing mothers patients with severe liver disease patients with severe lung disease patients with thyroid disease |
gptkbp:type_of |
81161-70-0
|